Published in Hepatology on June 01, 1999
Hepatoprotective role of PXR activation and MRP3 in cholic acid-induced cholestasis. Br J Pharmacol (2007) 1.23
Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression. Hepatology (2010) 0.98
From immunobiology to β-cell biology: the changing perspective on type 1 diabetes. Islets (2014) 0.88
Liver protective effect of ursodeoxycholic acid includes regulation of ADAM17 activity. BMC Gastroenterol (2013) 0.84
Ursodeoxycholic acid therapy in gallbladder disease, a story not yet completed. World J Gastroenterol (2013) 0.81
Effect of colitis and ileoanal pouch on biliary enrichment of ursodeoxycholic acid in primary sclerosing cholangitis. Dig Dis Sci (2006) 0.78
A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis. Medicine (Baltimore) (2016) 0.75
Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol (1978) 2.63
A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest (1998) 2.16
Quantitative estimation of the hydrophilic-hydrophobic balance of mixed bile salt solutions. J Lipid Res (1989) 2.10
Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology (1994) 2.10
Effect of sodium taurolithocholate on bile flow and bile acid exeretion. J Clin Invest (1968) 1.95
High pressure liquid chromatographic analysis of conjugated bile acids in human bile: simultaneous resolution of sulfated and unsulfated lithocholyl amidates and the common conjugated bile acids. J Lipid Res (1987) 1.51
The hydrophobic-hydrophilic balance of bile salts. Inverse correlation between reverse-phase high performance liquid chromatographic mobilities and micellar cholesterol-solubilizing capacities. J Lipid Res (1982) 1.41
Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. Gastroenterology (1989) 1.27
A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology (1995) 1.24
Conjugates of ursodeoxycholate protect against cholestasis and hepatocellular necrosis caused by more hydrophobic bile salts. In vivo studies in the rat. Gastroenterology (1991) 1.19
Transformation of chenodeoxycholic acid and ursodeoxycholic acid by human intestinal bacteria. Gastroenterology (1979) 1.17
Bile acid metabolism in mammals. I. Bile acid-induced intrahepatic cholestasis. Lab Invest (1971) 1.10
Hepatic taurine concentration and dietary taurine as regulators of bile acid conjugation with taurine. Gastroenterology (1978) 1.10
Pharmacology of ursodeoxycholic acid, an enterohepatic drug. Scand J Gastroenterol Suppl (1994) 1.07
Effect of deoxycholic acid ingestion on bile acid metabolism and biliary lipid secretion in normal subjects. Gastroenterology (1977) 1.04
Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration. Hepatology (1991) 1.02
Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis. Hepatology (1990) 1.02
Tauroursodeoxycholate prevents taurocholate induced cholestasis. Life Sci (1982) 0.97
Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy. Hepatology (1993) 0.96
Choleretic and cholestatic effects of infused bile salts in the rat. Experientia (1979) 0.95
Effect of ursodeoxycholate and its taurine conjugate on bile acid synthesis and cholesterol absorption. Gastroenterology (1984) 0.95
A prospective morphologic evaluation of hepatic toxicity of chenodeoxycholic acid in patients with cholelithiasis: the National Cooperative Gallstone Study. Hepatology (1982) 0.95
In vitro transformation of chenodeoxycholic acid and ursodeoxycholic acid by human intestinal flora, with particular reference to the mutual conversion between the two bile acids. J Lipid Res (1981) 0.90
Cholesterol 7alpha-hydroxylase (CYP7A): patterns of messenger RNA expression during rat liver development. Hepatology (1998) 0.87
Inhibition of bile formation by high doses of taurocholate in the perfused rat liver. Scand J Gastroenterol (1976) 0.86
Heterogeneous expression of cholesterol 7 alpha-hydroxylase and sterol 27-hydroxylase genes in the rat liver lobulus. J Clin Invest (1995) 0.86
Relationship between biliary and serum bile acids and response to ursodeoxycholic acid in patients with primary biliary cirrhosis. Am J Gastroenterol (1998) 0.85
Tauroursodeoxycholate prevents biliary protein excretion induced by other bile salts in the rat. Am J Physiol (1985) 0.83
Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response. J Hepatol (1996) 0.83
Metabolsim of steroid and amino acid moieties of conjugated bile acids in man. Gastroenterology (1974) 0.82
Ursodeoxycholic acid administration on bile acid metabolism in patients with early stages of primary biliary cirrhosis. Dig Dis Sci (1993) 0.81
Metabolism of steroid and amino acid moieties of conjugated bile acids in man. V. Equations for the perturbed enterohepatic circulation and their application. Gastroenterology (1977) 0.79
Effect of long-term treatment with ursodiol on clinical and biochemical features and biliary bile acid metabolism in patients with primary biliary cirrhosis. Am J Gastroenterol (1993) 0.78
The lack of relationship between hepatotoxicity and lithocholic-acid sulfation in biliary bile acids during chenodiol therapy in the National Cooperative Gallstone Study. Hepatology (1991) 0.78
Glycoursodeoxycholate is as effective as tauroursodeoxycholate in preventing the taurocholate-induced cholestasis in the rat. Res Commun Chem Pathol Pharmacol (1983) 0.77
Cholic acid and ursodeoxycholic acid therapy in primary biliary cirrhosis. Changes in bile acid patterns and their correlation with liver function. Eur J Clin Pharmacol (1993) 0.77
The effect of tauroursodeoxycholic acid and taurine supplementation on biliary bile acid composition. Hepatology (1983) 0.77
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med (1998) 14.40
International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol (1999) 9.11
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology (2001) 8.09
Tumorigenicity of virus-transformed cells in nude mice is correlated specifically with anchorage independent growth in vitro. Proc Natl Acad Sci U S A (1975) 6.59
Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med (1998) 6.23
Characterization of the fusion domain of the human immunodeficiency virus type 1 envelope glycoprotein gp41. Proc Natl Acad Sci U S A (1990) 4.64
Identification of the principal neutralizing determinant of human immunodeficiency virus type 1 as a fusion domain. J Virol (1991) 4.37
A nonselective analysis of SV40 transformation of mouse 3T3 cells. Virology (1974) 4.37
Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet (1999) 4.36
Dissolution of cholesterol gallstones by chenodeoxycholic acid. N Engl J Med (1972) 4.26
Logistic regression in the medical literature: standards for use and reporting, with particular attention to one medical domain. J Clin Epidemiol (2001) 4.20
Colonic secretion of water and electrolytes induced by bile acids: perfusion studies in man. J Clin Invest (1971) 4.18
Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med (1989) 4.07
International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet (2009) 3.89
Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med (2000) 3.74
Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med (1995) 3.69
Breath test for altered bile-acid metabolism. Lancet (1971) 3.60
Detergent properties of bile salts: correlation with physiological function. Annu Rev Med (1967) 3.25
Corticosteroid therapy of alcoholic hepatitis. Gastroenterology (1978) 3.21
Letter: A simple calculation of the lithogenic index of bile: expressing biliary lipid composition on rectangular coordinates. Gastroenterology (1973) 3.09
A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology (2001) 3.02
Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology (1990) 2.99
Increased reflux of bile into the stomach in patients with gastric ulcer. Gastroenterology (1969) 2.86
Assessment of hepatitis C viremia using molecular amplification technologies: correlations and clinical implications. Ann Intern Med (1995) 2.83
The syndrome of ileal disease and the broken enterohepatic circulation: cholerheic enteropathy. Gastroenterology (1967) 2.81
Hepatic lidocaine metabolism and liver histology in patients with chronic hepatitis and cirrhosis. Hepatology (1994) 2.81
Resource utilization in liver transplantation: effects of patient characteristics and clinical practice. NIDDK Liver Transplantation Database Group. JAMA (1999) 2.78
Role of bile acid malabsorption in pathogenesis of diarrhea and steatorrhea in patients with ileal resection. I. Response to cholestyramine or replacement of dietary long chain triglyceride by medium chain triglyceride. Gastroenterology (1972) 2.73
The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J Biol Chem (1998) 2.72
Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial. Ann Intern Med (1997) 2.69
Molecular pathogenesis of cholestasis. N Engl J Med (1998) 2.68
Transient symptomatic hypotension in patients on simvastatin. Lancet (1989) 2.67
Plasminogen activator production accompanies loss of anchorage regulation in transformation of primary rat embryo cells by simian virus 40. Proc Natl Acad Sci U S A (1974) 2.59
Mutational analysis of the cleavage sequence of the human immunodeficiency virus type 1 envelope glycoprotein precursor gp160. J Virol (1989) 2.58
Fulminant hepatic failure: summary of a workshop. Hepatology (1995) 2.53
Structural and functional polarity of canalicular and basolateral plasma membrane vesicles isolated in high yield from rat liver. J Cell Biol (1984) 2.47
Sensitivity and specificity in tests of distal ileal function: prospective comparison of bile acid and vitamin B 12 absorption in ileal resection patients. Gastroenterology (1973) 2.42
Cholestyramine treatment of diarrhea associated with ileal resection. N Engl J Med (1969) 2.40
Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry (2000) 2.34
Plastic bowing, torus and greenstick supracondylar fractures of the humerus: radiographic clues to obscure fractures of the elbow in children. Radiology (1978) 2.33
Right lobe living donor liver transplantation. Transplantation (1999) 2.31
Detection of retroviral antibodies in primary biliary cirrhosis and other idiopathic biliary disorders. Lancet (1998) 2.31
The chaperonin ATPase cycle: mechanism of allosteric switching and movements of substrate-binding domains in GroEL. Cell (1996) 2.28
Estimates of the frequency of chromosome abnormalities detectable in unselected newborns using moderate levels of banding. J Med Genet (1992) 2.27
Acquired hyperoxaluria, nephrolithiasis, and intestinal disease. Description of a syndrome. N Engl J Med (1972) 2.21
Deficiency of protein C in patients with portal vein thrombosis. Hepatology (1988) 2.19
Prospective comparison of indirect methods for detecting lactase deficiency. N Engl J Med (1975) 2.18
Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg (1997) 2.16
Second messenger cascade specificity and pharmacological selectivity of the human P2Y1-purinoceptor. Br J Pharmacol (1996) 2.12
A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology (1999) 2.11
Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology (1977) 2.10
Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology (1985) 2.09
Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology (1975) 2.08
The role of envelope glycoprotein processing in murine leukemia virus infection. J Virol (1987) 2.06
Cell fusion induced by the murine leukemia virus envelope glycoprotein. J Virol (1993) 2.05
Reducing infection transmission in solid organ transplantation through donor nucleic acid testing: a cost-effectiveness analysis. Am J Transplant (2013) 2.02
Triolein breath test: a sensitive and specific test for fat malabsorption. Gastroenterology (1979) 1.98
Efficacy and specificity of chenodeoxycholic acid therapy for dissolving gallstones. N Engl J Med (1973) 1.98
Hepatocyte transport of bile acids and organic anions in endotoxemic rats: impaired uptake and secretion. Gastroenterology (1997) 1.95
Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club. Gut (2005) 1.93
Comparative biochemistry of non-muscle actins. J Biol Chem (1977) 1.92
Measurements of intestinal permeability using low molecular weight polyethylene glycols (PEG 400). II. Application to normal and abnormal permeability states in man and animals. Gastroenterology (1977) 1.92
Budd-Chiari syndrome: etiology, diagnosis and management. Medicine (Baltimore) (1982) 1.92
Outpatient liver biopsy: how safe is it? Ann Intern Med (1993) 1.90
Improved method for bacteriological diagnosis of spontaneous bacterial peritonitis. J Clin Microbiol (1989) 1.90
Phosphoinositide hydrolysis by guanosine 5'-[gamma-thio]triphosphate-activated phospholipase C of turkey erythrocyte membranes. Biochem J (1988) 1.88
Simultaneous measurements of total pancreatic, biliary, and gastric outputs in man using a perfusion technique. Gastroenterology (1970) 1.86
Interpretation of automated perimetry for glaucoma by neural network. Invest Ophthalmol Vis Sci (1994) 1.86
Synthesis, biological activity, and molecular modeling of ribose-modified deoxyadenosine bisphosphate analogues as P2Y(1) receptor ligands. J Med Chem (2000) 1.85
Identification of potent, selective P2Y-purinoceptor agonists: structure-activity relationships for 2-thioether derivatives of adenosine 5'-triphosphate. J Med Chem (1993) 1.84
P2-purinergic receptors: subtype-associated signaling responses and structure. Annu Rev Pharmacol Toxicol (1995) 1.84
Monooctanoin, a dissolution agent for retained cholesterol bile duct stones: physical properties and clinical application. Gastroenterology (1980) 1.84
The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis. Gastroenterology (1997) 1.83
Sarcoidosis and chronic hepatic disease: a clinical and pathologic study of 20 patients. Medicine (Baltimore) (1970) 1.82
Radioimmunoassay of conjugated cholyl bile acids in serum. Gastroenterology (1973) 1.81
Abelson virus-induced lymphomagenesis in mice. J Exp Med (1978) 1.81
Alcoholic hepatitis. Cell-mediated immunological response to alcoholic hyalin. Gastroenterology (1976) 1.78
Sclerosing cholangitis: biliary reconstruction with Silastic transhepatic stents. Surgery (1983) 1.77
Isolated rat hepatocyte couplets: a primary secretory unit for electrophysiologic studies of bile secretory function. Proc Natl Acad Sci U S A (1984) 1.77
Prospective, randomized, endoscopic-blinded trial comparing precolonoscopy bowel cleansing methods. Dis Colon Rectum (1994) 1.76
Expression of a cloned P2Y purinergic receptor that couples to phospholipase C. Mol Pharmacol (1994) 1.76
Peliosis hepatis associated with androgenic-anabolic steroid therapy. A severe form of hepatic injury. Ann Intern Med (1974) 1.75
Agonist action of adenosine triphosphates at the human P2Y1 receptor. Mol Pharmacol (1998) 1.74
Portal hypertension and variceal bleeding: an AASLD single topic symposium. Hepatology (1998) 1.74
Mechanisms and regulation of bile secretion. Hepatology (1991) 1.74
The natural history of portal hypertension after transjugular intrahepatic portosystemic shunts. Gastroenterology (1997) 1.74
Persistent hepatitis C virus infection after liver transplantation: clinical and virological features. Hepatology (1995) 1.74
Effect of glycine-conjugated bile acids with and without lecithin on water and glucose absorption in perfused human jejunum. J Clin Invest (1973) 1.73
Improved reliability of lymphoma diagnostics via PCR-based clonality testing: report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia (2006) 1.72
Activity of recombinant dengue 2 virus NS3 protease in the presence of a truncated NS2B co-factor, small peptide substrates, and inhibitors. J Biol Chem (2001) 1.72
Cardiopulmonary resuscitation in the delivery room. Associated clinical events. Arch Pediatr Adolesc Med (1995) 1.71
Is the current classification of venous thromboembolism acceptable? No. J Thromb Haemost (2004) 1.70
The cervical aortic arch. Am J Roentgenol Radium Ther Nucl Med (1975) 1.68